BRKR
Company Description
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.44B | 3.37B | 2.96B | 2.53B | 2.42B | 1.99B | 2.07B | 1.90B | 1.77B | 1.61B | 1.62B | 1.81B |
| Net Income | (8.60M) | 113.10M | 427.20M | 296.60M | 277.10M | 157.80M | 197.20M | 179.70M | 78.60M | 153.60M | 101.60M | 56.70M |
| EPS | -0.15 | 0.76 | 2.92 | 2.00 | 1.83 | 1.03 | 1.27 | 1.15 | 0.50 | 0.95 | 0.60 | 0.34 |
| Free Cash Flow | 43.30M | 136.00M | 243.20M | 145.20M | 190.40M | 235.00M | 140.40M | 190.50M | 110.70M | 93.70M | N/A | N/A |
| FCF / Share | 0.29 | 0.91 | 1.66 | 0.98 | 1.26 | 1.53 | 0.90 | 1.22 | 0.70 | 0.58 | N/A | N/A |
| Operating CF | 134.10M | 251.30M | 350.10M | 274.40M | 282.40M | 332.20M | 213.40M | 239.70M | 154.40M | 130.80M | N/A | N/A |
| Total Assets | 6.24B | 5.81B | 4.25B | 3.61B | 3.65B | 3.05B | 2.77B | 2.13B | 1.95B | 1.81B | N/A | N/A |
| Total Debt | 2.04B | 2.25B | 1.38B | 1.27B | 1.39B | 912.80M | 880.90M | 341.10M | 415.60M | 411.70M | N/A | N/A |
| Cash & Equiv | 298.80M | 183.40M | 488.30M | 645.50M | 1.07B | 681.80M | 678.30M | 322.40M | 325.00M | 342.40M | N/A | N/A |
| Book Value | 2.46B | 1.78B | 1.38B | 1.11B | 1.07B | 961.20M | 906.80M | 905.10M | 733.50M | 693.10M | N/A | N/A |
| Return on Equity | -0.00 | 0.06 | 0.31 | 0.27 | 0.26 | 0.16 | 0.22 | 0.20 | 0.11 | 0.22 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 823.40M | 977.20M | 860.50M | 797.40M | 801.40M | 979.60M | 864.40M | 800.70M | 721.70M | 854.50M | 742.80M | 681.90M |
| Net Income | 14.40M | 26.00M | (59.60M) | 7.60M | 17.40M | 13.70M | 40.90M | 7.60M | 50.90M | 205.50M | 88.10M | 57.10M |
| EPS | 0.02 | 0.10 | -0.41 | 0.05 | 0.11 | 0.09 | 0.27 | 0.05 | 0.35 | 1.41 | 0.60 | 0.39 |
| Free Cash Flow | 47.00M | 207.20M | (54.10M) | (148.80M) | 39.00M | 153.30M | 5.80M | (23.50M) | 400,000 | 174.00M | 17.20M | (10.50M) |
| FCF / Share | 0.31 | 1.36 | -0.36 | -0.98 | 0.26 | 1.01 | 0.04 | -0.16 | 0.00 | 1.20 | 0.12 | -0.07 |
| Operating CF | 71.20M | 229.80M | (33.20M) | (127.50M) | 65.00M | 190.00M | 38.40M | 1.10M | 21.80M | 205.50M | 44.10M | 13.00M |
| Total Assets | 6.13B | 6.24B | 6.43B | 6.34B | 5.93B | 5.81B | 6.11B | 5.90B | 4.51B | 4.25B | 3.82B | 3.86B |
| Total Debt | 1.67B | 2.04B | 2.01B | 2.44B | 2.11B | 2.25B | 2.42B | 2.27B | 1.46B | 1.38B | 1.22B | 1.24B |
| Cash & Equiv | 133.40M | 298.80M | 293.10M | 92.00M | 184.20M | 183.40M | 148.10M | 169.70M | 340.10M | 488.30M | 363.60M | 574.80M |
| Book Value | 2.45B | 2.46B | 2.43B | 1.80B | 1.82B | 1.78B | 1.81B | 1.79B | 1.42B | 1.38B | 1.21B | 1.23B |
| Return on Equity | 0.01 | 0.01 | -0.02 | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 | 0.04 | 0.15 | 0.07 | 0.05 |